# Psychedelics Policy: Resources

This section provides a curated list of key research, reports, and sources on psychedelics policy, clinical evidence, and regulatory frameworks.

---

## Academic Research

### Peer-Reviewed Studies -- Psilocybin

- Goodwin, G.M., et al. "Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression." *New England Journal of Medicine* 387 (2022): 1637-1648. <https://doi.org/10.1056/NEJMoa2206443>
- Davis, A.K., et al. "Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial." *JAMA Psychiatry* 78, no. 5 (2021): 481-489. <https://doi.org/10.1001/jamapsychiatry.2020.3285>
- Raison, C.L., et al. "Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial." *JAMA* 330, no. 9 (2023): 843-853. <https://doi.org/10.1001/jama.2023.14530>
- Griffiths, R.R., et al. "Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer." *Journal of Psychopharmacology* 30, no. 12 (2016): 1181-1197. <https://doi.org/10.1177/0269881116675513>
- Bogenschutz, M.P., et al. "Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder." *JAMA Psychiatry* 79, no. 10 (2022): 953-962. <https://doi.org/10.1001/jamapsychiatry.2022.2096>
- Johnson, M.W., et al. "Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction." *Journal of Psychopharmacology* 28, no. 11 (2014): 983-992. <https://doi.org/10.1177/0269881114548296>
- Griffiths, R.R., et al. "Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance." *Psychopharmacology* 187, no. 3 (2006): 268-283. <https://doi.org/10.1007/s00213-006-0457-5>

### Peer-Reviewed Studies -- MDMA

- Mitchell, J.M., et al. "MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study." *Nature Medicine* 27 (2021): 1025-1033. <https://doi.org/10.1038/s41591-021-01336-3>
- Mitchell, J.M., et al. "MDMA-Assisted Therapy for Moderate to Severe PTSD: A Randomized, Placebo-Controlled Phase 3 Trial." *Nature Medicine* 29 (2023): 2473-2480. <https://doi.org/10.1038/s41591-023-02565-4>
- Mithoefer, M.C., et al. "MDMA-Assisted Psychotherapy for Treatment of PTSD: Study Design and Rationale for Phase 3 Trials Based on Pooled Analysis of Six Phase 2 Randomized Controlled Trials." *Psychopharmacology* 236 (2019): 2735-2745.

### Peer-Reviewed Studies -- LSD and Other Compounds

- Holze, F., et al. "LSD Acutely Impairs Working Memory, Executive Functions, and Cognitive Flexibility, but Not Risk-Based Decision-Making." *Psychological Medicine* 51, no. 13 (2021): 2255-2264.
- Davis, A.K., et al. "Ibogaine Treatment Outcomes for Opioid Dependence from a Twelve-Month Observational Study." *Nature* 2024 (preliminary results).

### Reviews and Meta-Analyses

- Nutt, D.J., et al. "Effects of Schedule I Drug Laws on Neuroscience Research and Treatment Innovation." *Nature Reviews Neuroscience* 14 (2013): 577-585. - Foundational analysis of how scheduling impedes research
- Carhart-Harris, R.L., and Goodwin, G.M. "The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future." *Neuropsychopharmacology* 42 (2017): 2105-2113.
- Reiff, C.M., et al. "Psychedelics and Psychedelic-Assisted Psychotherapy." *American Journal of Psychiatry* 177, no. 5 (2020): 391-410. - Comprehensive review in leading psychiatry journal

### Working Papers and White Papers

- RAND Corporation. "Psychedelic-Assisted Therapy: Policy Considerations for the United States." Working Paper. 2024.
- Brookings Institution. "Regulatory Frameworks for Psychedelic Therapy: Lessons from International Experience." 2023.

---

## Government Reports and Data

### Federal Agencies

- FDA. "Draft Guidance for Industry: Psychedelic Drugs -- Considerations for Clinical Investigations." June 2023. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>
- FDA Advisory Committee. "Proceedings: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee -- MDMA-Assisted Therapy for PTSD." June 4, 2024.
- Government Accountability Office. "Drug Research: DEA Can Improve Its Review Process for Researchers." GAO-22-104627. 2022.
- SAMHSA. "National Survey on Drug Use and Health (NSDUH) 2023: Detailed Tables." 2024. <https://www.samhsa.gov/data/release/2023-national-survey-drug-use-and-health-nsduh-releases>
- NIDA. "Psychedelic and Dissociative Drugs." Research Topics page. <https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs>
- VA National Center for PTSD. "How Common Is PTSD in Adults?" 2024. <https://www.ptsd.va.gov/understand/common/common_adults.asp>
- CDC WONDER. "Multiple Cause of Death Data." Updated annually. <https://wonder.cdc.gov>

### Congressional Reports

- Congressional Research Service. "Psychedelic Drugs: Overview and Selected Policy Issues." Report R47742. 2024. <https://crsreports.congress.gov>
- Congressional Research Service. "The Federal Drug Scheduling System." Report R45948. Updated 2024.

### Agency Data Portals

- ClinicalTrials.gov. Registry of all registered clinical trials. <https://clinicaltrials.gov> - Search "psilocybin" or "MDMA" for current trial listings
- DEA. Controlled Substances by CSA Schedule. <https://www.deadiversion.usdoj.gov>
- Oregon Psilocybin Services. Program data and reports. <https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Services.aspx>

---

## Books

- Pollan, Michael. *How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence*. Penguin Press, 2018. - Bestselling book that brought psychedelic research to mainstream audiences
- Shroder, Tom. *Acid Test: LSD, Ecstasy, and the Power to Heal*. Blue Rider Press, 2014. - History of MDMA therapy and MAPS
- Doblin, Rick. *Psychedelic Medicine: The Healing Power of LSD, MDMA, Psilocybin, and Ayahuasca*. Park Street Press, 2022. - By the founder of MAPS
- Fadiman, James. *The Psychedelic Explorer's Guide*. Park Street Press, 2011. - Practical and historical guide
- Sessa, Ben. *The Psychedelic Renaissance: Reassessing the Role of Psychedelic Drugs in 21st Century Psychiatry and Society*. Muswell Hill Press, 2017.
- Grob, Charles S., and Grinspoon, Lester, eds. *Hallucinogens: A Reader*. TarcherPerigee, 2002. - Collection of foundational texts
- Lee, Martin A., and Shlain, Bruce. *Acid Dreams: The Complete Social History of LSD*. Grove Press, 1985. - Definitive history of LSD including MKUltra

---

## Think Tank Analysis

### Research Organizations

- Drug Policy Alliance. "Psychedelics: Policy Considerations for Therapeutic and Personal Use." 2023. <https://drugpolicy.org> - Comprehensive reform framework
- RAND Corporation. "Evidence Review: Psychedelic-Assisted Therapy for Mental Health Conditions." 2024. <https://www.rand.org>
- Brookings Institution. "The Psychedelic Policy Landscape: Federal, State, and International Developments." 2024. <https://www.brookings.edu>
- Cato Institute. Greenwald, Glenn. "Drug Decriminalization in Portugal: Lessons for Creating Fair and Successful Drug Policies." 2009. <https://www.cato.org/white-paper/drug-decriminalization-portugal>

### Policy Briefs

- Third Way. "The Case for Psychedelic Therapy Reform." 2023. <https://www.thirdway.org>
- R Street Institute. "Psychedelic Policy Reform: A Conservative Case." 2023. <https://www.rstreet.org>
- Reason Foundation. "Removing Barriers to Psychedelic Research and Therapy." 2024. <https://reason.org>

---

## Organizations and Advocacy Groups

| Organization | Focus | Type | Website |
|--------------|-------|------|---------|
| MAPS (Multidisciplinary Association for Psychedelic Studies) | MDMA therapy research; psychedelic policy reform | Nonprofit research and advocacy | <https://maps.org> |
| Usona Institute | Psilocybin research for depression (public benefit model) | Nonprofit research | <https://www.usonainstitute.org> |
| Heffter Research Institute | Funding psychedelic research at academic centers | Nonprofit research funder | <https://heffter.org> |
| Johns Hopkins Center for Psychedelic and Consciousness Research | Academic psychedelic research | Academic research center | <https://hopkinspsychedelic.org> |
| Drug Policy Alliance | Broad drug policy reform including psychedelics | Advocacy | <https://drugpolicy.org> |
| Heroic Hearts Project | Connecting veterans with psychedelic therapy | Veteran advocacy/nonprofit | <https://www.heroicheartsproject.org> |
| VETS (Veterans Exploring Treatment Solutions) | Veteran access to psychedelic therapy | Veteran advocacy | <https://vfrfoundation.org> |
| Students for Sensible Drug Policy | Campus-based drug policy reform | Student advocacy | <https://ssdp.org> |
| Decriminalize Nature | Municipal decriminalization campaigns | Grassroots advocacy | <https://www.decriminalizenature.org> |
| Indigenous Peyote Conservation Initiative | Peyote conservation and indigenous rights | Indigenous advocacy | Various |
| Beckley Foundation | International psychedelic research and policy | UK-based research and policy | <https://www.beckleyfoundation.org> |
| Compass Pathways | Psilocybin therapy development (COMP360) | For-profit pharmaceutical | <https://www.compasspathways.com> |

---

## Data Sources

| Dataset | Provider | Update Frequency | URL | Description |
|---------|----------|------------------|-----|-------------|
| National Survey on Drug Use and Health (NSDUH) | SAMHSA | Annual | <https://www.samhsa.gov/data/nsduh> | Nationally representative survey on drug use, mental illness, and treatment |
| ClinicalTrials.gov | NIH/NLM | Continuous | <https://clinicaltrials.gov> | Registry of all clinical trials including psychedelic studies |
| CDC WONDER Multiple Cause of Death | CDC | Annual | <https://wonder.cdc.gov> | Drug overdose and cause-of-death data |
| Oregon Psilocybin Services Reports | Oregon Health Authority | Quarterly | <https://www.oregon.gov/oha> | Oregon program data: licenses, sessions, outcomes |
| Global Drug Survey | Independent | Annual | <https://www.globaldrugsurvey.com> | International self-report survey on drug use patterns and harms |
| IQVIA Prescription Data | IQVIA | Monthly | <https://www.iqvia.com> | Pharmaceutical prescription and market data |

---

## News and Journalism

### Investigative Reports

- New York Times. "The Psychedelic Revolution Is Coming. Will It Be Accessible to All?" Series, 2023-2024. - Covers equity and access challenges
- STAT News. "Psychedelics Coverage." Ongoing. <https://www.statnews.com/tag/psychedelics/> - Leading health journalism outlet covering psychedelic research and policy
- Wired. "Inside the Psychedelic Therapy Movement." 2023. - In-depth technology and science reporting

### Ongoing Coverage

- *STAT News*. Psychedelics beat coverage. <https://www.statnews.com> - Most consistent, rigorous coverage of clinical and regulatory developments
- *The New York Times*. Health and drug policy sections. Periodic in-depth features on psychedelic research
- *The Atlantic*. Long-form coverage of psychedelic science and culture
- *Lucid News*. <https://www.lucid.news> - Dedicated psychedelics journalism outlet

---

## International Sources

- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). "European Drug Report." Annual. <https://www.emcdda.europa.eu>
- Australian Therapeutic Goods Administration. "Psilocybin and MDMA Rescheduling Decision." 2023. <https://www.tga.gov.au>
- United Nations Office on Drugs and Crime (UNODC). "World Drug Report." Annual. <https://www.unodc.org/wdr>
- Health Canada. "Special Access Programme: Psilocybin and MDMA." <https://www.canada.ca/en/health-canada.html>

---

## Legal Resources

### Case Law

- *Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal*, 546 U.S. 418 (2006). - Unanimous Supreme Court ruling protecting religious ayahuasca use under RFRA
- *Church of the Holy Light of the Queen v. Mukasey*, 615 F.Supp.2d 1210 (D. Or. 2009). - Federal court injunction protecting Santo Daime ayahuasca use
- *Employment Division v. Smith*, 494 U.S. 872 (1990). - Supreme Court ruling on religious use of peyote (later superseded by RFRA)
- *MDMA Scheduling Hearing*, DEA Administrative Law Judge Francis Young (1985). - ALJ recommended Schedule III; DEA Administrator overruled to Schedule I

### Statutory References

- 21 U.S.C. Section 812 - Controlled Substances Act schedules (Schedule I definition and substance listing)
- 21 U.S.C. Section 811 - Attorney General scheduling authority and procedures
- 42 U.S.C. Section 1996a - American Indian Religious Freedom Act Amendments (peyote exemption)
- 42 U.S.C. Section 2000bb - Religious Freedom Restoration Act (basis for ayahuasca decisions)
- Oregon Revised Statutes Chapter 475A - Oregon Psilocybin Services Act
- Colorado Revised Statutes Title 12, Article 170 - Natural Medicine Health Act

---

## Document Navigation

- Up: [Drug Policy](../01-overview.md)
- Previous: [Roadmap](08-roadmap.md)
- Next: [Actions](10-actions.md)
